{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:44:16Z","timestamp":1785897856392,"version":"3.56.0"},"reference-count":19,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T00:00:00Z","timestamp":1440547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Recent advances have yielded multiple new life\u2010prolonging treatments for men with metastatic castration\u2010resistant prostate cancer (mCRPC) including chemotherapy, next\u2010generation hormonal therapy, immunotherapy, and radiopharmaceutical products. However, the optimal sequencing of these agents to maximize clinical benefit remains unclear. Recent data from the CHAARTED and STAMPEDE studies suggest that early use of docetaxel in men with metastatic hormone\u2010sensitive prostate cancer (mHSPC) significantly improves survival, but whether early compared with delayed use of chemotherapy also provides a survival advantage in mCRPC is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A retrospective analysis of consecutive mCRPC patients treated at Johns Hopkins is reported. Patients included were treated with sequential docetaxel and abiraterone, in either order. The combined progression\u2010free survival (combined PFS: PFS1\u2009+\u2009PFS2) of abiraterone\u2010to\u2010docetaxel is compared to the reverse sequence, where PFS1 and PFS2 represent progression\u2010free survival on the first and second agents respectively. Overall survival (OS) from the start of the first therapy to death is compared between groups. Baseline characteristics are reported prior to the start of the first agent in the sequence. Propensity score\u2010weighted multivariable models and Kaplan\u2014Meier analysis are used for evaluation of the primary and secondary outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Fifty\u2010eight patients who began treatment for mCRPC between January 2011 (the year of abiraterone's FDA\u2010approval) and February 2015 were identified: 26 were in the docetaxel\u2010to\u2010abiraterone group and 32 were in the abiraterone\u2010to\u2010docetaxel group. Patients in the abiraterone\u2010to\u2010docetaxel group had more Gleason 8\u201310 tumors, greater metastatic burden in bone, and higher median PSAs than those in the docetaxel\u2010to\u2010abiraterone group. Propensity score\u2010weighted univariate analyses for combined PFS (HR 0.82; 95%CI 0.50\u20131.33; <jats:italic>P\u2009<\/jats:italic>=\u20090.41) and OS (HR 0.79; 95%CI 0.50\u20131.25; <jats:italic>P\u2009<\/jats:italic>=\u20090.31) do not identify any significant differences based on treatment sequence. Propensity score\u2010weighted multivariate analyses for combined PFS (HR 0.91; 95%CI 0.52\u20131.60; <jats:italic>P\u2009<\/jats:italic>=\u20090.74) and OS (HR 0.98; 95%CI 0.59\u20131.63; <jats:italic>P\u2009<\/jats:italic>=\u20090.95) also do not identify any significant differences between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>We do not observe differences in clinical outcomes based on alternative sequencing of abiraterone and docetaxel in men with mCRPC. Treatment sequencing should be determined by patient and disease characteristics, comorbidities and end\u2010organ function, ability to tolerate side effects, and patient preferences. Studies evaluating biomarkers to inform optimal treatment sequencing in men with mCRPC are urgently needed. <jats:italic>Prostate 75:1814\u20131820, 2015<\/jats:italic>. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.23064","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T09:39:20Z","timestamp":1440581960000},"page":"1814-1820","source":"Crossref","is-referenced-by-count":15,"title":["Optimal sequencing of docetaxel and abiraterone in men with metastatic castration\u2010resistant prostate cancer"],"prefix":"10.1002","volume":"75","author":[{"given":"Benjamin L.","family":"Maughan","sequence":"first","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian C.","family":"Xhou","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Suzman","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Nadal","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunakshi","family":"Bassi","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology University of Washington\/Fred Hutchinson Cancer Research Center Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,8,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5001","article-title":"Docetaxel and\/or zoledronic acid for hormone\u2010naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476)","volume":"33","author":"James ND","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22874"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.042"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28518"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1055249"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032514"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-12-0238"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70033-1"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22872"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds119"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.018"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu336.39","article-title":"Sequencing of docetaxel (D) and abiraterone acetate (AA) for metastatic castration\u2010resistant prostate cancer (mCRPC)","volume":"25","author":"Zafeiriou Z","year":"2014","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology \/ ESMO"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28270"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00011-X"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba5002","article-title":"A phase III protocol of androgen suppression (AS) and 3DCRT\/IMRT versus AS and 3DCRT\/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high\u2010risk prostate cancer (RTOG 0521)","volume":"33","author":"Sandler HM","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1341"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23064","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:55:37Z","timestamp":1696524937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,26]]},"references-count":19,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/pros.23064"],"URL":"https:\/\/doi.org\/10.1002\/pros.23064","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,26]]}}}